In most tissues, cells are exposed to frequent changes in levels of oxidative stress and inflammation. Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and nuclear factor-κB (NF-κB) are the two key transcription factors that regulate cellular responses to oxidative stress and inflammation respectively. Pharmacological and genetic studies suggest that there is functional cross-talk between these two important pathways. The absence of Nrf2 can exacerbate NF-κB activity leading to increased cytokine production, whereas NF-κB can modulate Nrf2 transcription and activity, having both positive and negative effects on the target gene expression. This review focuses on the potentially complex molecular mechanisms that link the Nrf2 and NF-κB pathways and the importance of designing more effective therapeutic strategies to prevent or treat a broad range of neurological disorders.
The human Keap1 protein contains 27 cysteine resides, some of which act as sensors of oxidative stress. Oxidizing and electrophilic agents, such as free ROS and plant-derived phenolic compounds, among many others, can modify these cysteine residues [9] . This causes a conformational change in Keap1, preventing subsequent binding of newly synthesized Nrf2, which promptly accumulates in the nucleus [10] . There, Nrf2 associates with small Maf proteins (sMaf) and binds to antioxidant responsive elements (ARE) in the promoters of its target genes. This process is essential for the assembly of the RNA polymerase machinery and the initiation of transcription [11] . What happens to Nrf2 next remains to be determined in more detail; however, Nrf2 can either be degraded in the nucleus via the β-TrCP-GSK3β axis or alternatively it may translocate back to the cytoplasm where it is swiftly degraded by Keap1 [12, 13] .
The NF-κB cellular function and regulation
Nuclear factor-κB (NF-κB) is a family of transcription factors that includes RelA (p65), RelB, c-rel, p50 and p52 [14] . The NF-κB complex is a key transcription factor that mediates immune responses to bacterial and viral infections, inflammation, aspects of development, cell proliferation and protection against UV radiation [15] . Proinflammatory cytokines such as tumour necrosis factor (TNF)α, interleukin (IL)-1β and bacterial lipopolysaccharide (LPS) are among the most potent NF-κB activators, acting on the extracellular receptors and initiating a relay of intracellular phosphorylation events, which co-ordinate signalling and conditional cell responses [16] . Phosphorylation of IκBα, the negative regulator of NF-κB, prompts an interaction with the β-TrCP-Skp1-Cullin1 complex driving IκBα ubiqitination and proteasomal degradation, releasing NF-κB subunits, which then translocate to the nucleus [17] . NF-κB homoand hetero-dimers associate specifically with κB regulatory DNA consensus sequences upstream of NF-κB target genes, including IκBα an early-transcribed gene, which chaperones NF-κB back to the cytoplasm [18] .
In order to respond effectively to acute inflammation, NF-κB also prompts an increase in mitochondrial activity and NADPH oxidase expression, which are the main sources of the endogenous free radicals [19, 20] .
It is now clear that robust NF-κB and Nrf2 activity is essential for maintaining co-ordinated cellular responses to resolve the inflammatory status of the cell/tissue. Imbalance between Nrf2 and NF-κB pathways is associated with a significant number of diseases ranging from neurodegeneration, autoimmune disorders and cancer [21] . It is well recognized that the Nrf2 and NF-κB pathways must interplay through multiple molecular interactions, the complexity and consequences of which are discussed below.
The interplay between Nrf2 and NF-κB pathways
The first insight into the interconnected nature of Nrf2 and NF-κB pathways came from the study of the Nrf2 knockout (KO) mice, which exhibit a neurodegenerative phenotype. Additionally, in the experimental model of brain injury the lack of Nrf2 has been associated with the augmentation of cytokine production [22] . Moreover, LPS-treated astrocytic and microglial cultures show more pronounced NF-κB activity compared with wild-type cells. The resulting elevation of cytokine production contributes to astrogliosis, neuronal death and demyelination of neuronal axons, which is an underlying cause of the neurodegenerative phenotype of the Nrf2 KO animals [23, 24] . Also, studies on Nrf2 − / − MEFs revealed enhanced IKKβ activity, augmenting the phosphorylation of IκBα and its subsequent degradation [25] . Both Nrf2 and NF-κB are regulated by redox sensitive factors and the absence of Nrf2 is associated with increased oxidative and nitrosative stress, leading to amplification of cytokine production, as NF-κB is more readily activated in oxidative environments [26] .
There have been numerous studies conducted on Nrf2 activating phytochemicals such as sulforaphane (SFP), which is abundant in cruciferous vegetables, as well as synthetic inducers such as 2-cyano-3,12 dioxooleana-1,9 dien-28-imidazolide (CDDO-Im) and their antiinflammatory potential. Pre-stimulation of Nrf2 in primary peritoneal macrophages dampens the production of COX-2 (cyclooxygenase 2), TNFα, iNOS (inducible nitric oxide synthase) and IL-1β in response to LPS. This effect has been attributed to Nrf2 activation, as the Nrf2 − / − macrophages do not exhibit this anti-inflammatory capacity [27] . What is more, the increase inNrf2 activity in lupus nephritis leads to the accumulation of glutathione (GSH), which effectively buffers free radicals and prevents the activation of p65, resulting in reduced deposition of extracellular matrix [28] . Levels of GSH are thought to decrease with age and it is a likely contributing factor to the exacerbation of diseases underlined by chronic inflammation [29] .
HO-1 is an Nrf2 target gene, which is at the core of Nrf2-mediated NF-κB inhibition. This enzyme is involved in haeme metabolism by catalysing the cleavage of the porphyrin ring of haeme into Fe 2 + , carbon monoxide and biliverdin, which is consequently converted into bilirubin. Increases in HO-1 activity in endothelial cells leads to inhibition of NF-κB-mediated transcription of adhesion molecules such as ESelectin and vascular cell adhesion molecule 1 (VCAM-1), through the action of bilirubin and possibly by the decrease in free intracellular iron ions [30] . A summary of known points of molecular cross-talk between Nrf2 and NF-κB is presented in Figure 1 .
P65 and its role in modulating Nrf2 activity
The anti-inflammatory role of Nrf2 is well established; however, it should be noted that NF-κB activity also regulates Nrf2-mediated ARE expression. The modulatory action of NF-κB activation is somewhat complex and appears to be cell type dependent. There are several mechanisms by which p65 (the canonical NF-κB subunit) can exert a negative effect on ARE-linked gene expression. Work by Yu et al. [31] has shown that p65 assists in increasing the abundance of nuclear Keap1 levels. The localization of Keap1 is thought to be mostly cytoplasmic, however the authors demonstrated that in cells overexpressing p65, Keap1 diminished Nrf2-ARE signalling by translocating to the nucleus [31] . As the nuclear envelope does not permit free entry of proteins larger than 40 kDa, Keap1 is thought to enter the nucleus by interactions with the import facilitating karyopherin alpha 6 (importin alpha 7) (otherwise known as KPNA6) [32] . Consequently, KPNA6 overexpression results in decreased levels of HO-1 and NQO1. However, the ability of Keap1 to enter nuclear space and its potential nuclear functions are not well defined and remain to be studied in more detail.
The most well-established mechanism of inhibition of Nrf2 by p65 activity is a competition of both proteins for the transcriptional co-activator CBP (CREB-binding protein)-p300 complex. The CBP-p300 has an intrinsic histone acetyl transferase activity, which leads to local acetylation of histones and the loosening of chromatin structure, exposing DNA for transcriptional apparatus assembly. Aside from its role in histone modifications, it also acetylates non-histone proteins, with Nrf2 and p65 being well-defined targets [33, 34] . The lysine residues in both transcription factors are subjected to acetyl group addition, which is thought to augment assembly of the transcriptional machinery and to enhance gene transcription [35] . CBP has been shown to interact with the Neh4 and Neh5 domains within Nrf2, which leads to the acetylation of the Neh1 domain, the DNA-binding portion of Nrf2. On the other hand, CBP also displays preference of binding to phosphorylated p65 at Ser 276 . Overexpression of p65 is thought to limit the availability of CBP for Nrf2 complex formation, prioritizing transcription of the κB driven genes. Consequently, knockdown of p65 promotes the Nrf2-CBP association [34] . Nrf2 reciprocates this competition and the application of ethyl pyruvate on BV2 cells was shown to increase Nrf2 binding to CBP, thus depriving its interaction with p65, thereby further decreasing expression of NF-κB target genes such as iNOS [36] .
In addition, p65 can induce repression of transcription by de-acetylation of histones, through association with histone deacetylase (HDAC). Liu et al. [34] also demonstrated that aside from competitive binding to CBP, p65 can promote HDAC3 association with MafK, thus preventing heterodimer formation with Nrf2 and therefore decreasing expression of ARE-related genes.
As stated previously, p65 is currently thought to have a dual role in the regulation of Nrf2 activity. Specific cell types show induction of Nrf2 protein levels and increased target gene expression in response to TNFα. Rushworth et al. [37] demonstrated that Nrf2 contains several κB sites in its proximal promoter, which are subject to binding and transcription initiation by p65. This underlies high basal Nrf2 activity in AML (acute myeloid leukaemia) cells and is believed to be the prime cause of chemoresistance of AML cells to the treatment with bortezomib [37] .
The modulation of Nrf2 in response to NF-κB activation can act as a protective mechanism against the consequences of inflammation. Cuadrado et al. [38] established that the small GTPase RAC1 (Ras-related C3 botulinum toxin substrate 1) plays a key role in this process. RAC1 activation by LPS can activate Nrf2-mediated HO-1 expression, which in turn dampens the pro-inflammatory activity of NF-κB. RAC1 can also cause an NF-κB-mediated increase in Nrf2 levels, which is necessary for the resolution of the NF-κB activity, shifting the redox balance of the cell towards a more reducing environment [38] .
Protein interactors linking the NF-κB and Nrf2 pathway
Aside from its regulatory role in the Nrf2-ARE pathway, Keap1 has been found to interact and negatively regulate IKKβ. IKKβ is targeted for degradation through autophagy in the absence of HSP90 (heat shock protein 90), which is a chaperone protein assisting in protein folding. Keap1 is thought to prevent HSP90 binding to IKKβ, which triggers its autophagic degradation. Additionally, Keap1 decreases the phosphorylation of IKKβ possibly by concealing the residues to which phosphate groups are otherwise attached. Overall, the outcome of the Keap1-IKKβ interaction is the negative regulation of NF-κB though stabilization of IKBα [39] .
Keap1 is thought to deplete Nrf2 from the cytoplasm, however the F-box protein β-TrCP, a component of the Skp1-Cullin1-β-TrCP E3 ligase complex, controls nuclear Nrf2 levels [12, 40] . The mechanism of degradation via β-TrCP differs considerably from the Keap1 mode of action as it only recognizes and binds to phosphorylated substrates. The kinase that phosphorylates and marks Nrf2 for β-TrCP binding is GSK3β. Interestingly, p65 is also a substrate for GSK3β phosphorylation, which is thought to modulate p65 DNA binding affinity, but can have both positive and negative effects on NF-κB depending on the cellular context [41, 42] .
The canonical role of β-TrCP is the regulation of IκBα degradation in response to cytokines [17] . Therefore, β-TrCP function can lead to augmentation of NF-κB activity as well as to inhibition of Nrf2-ARE transcription.
Another Nrf2 target gene, p62 is involved in modulation of antioxidant and inflammatory activities. p62 also acts as a protein scaffold, enhancing Nrf2 activity by mediating the autophagosomal degradation of Keap1 [43] . The ability of p62 to oligomerize, promotes ubiquitination and activation of TNFα receptor-associated factor 6 (TRAF6), enhancing nerve growth factor (NGF)-mediated NF-κB signalling [44] .
Finally, Nrf2 is thought to act mainly as a dimer with sMaf proteins, one of them being MafK has been shown to modulate transcriptional activity of p65. MafK is thought to facilitate the interaction of p65 and CBP, leading to increases in acetylation of p65 and its overexpression augments production of cytokines in response to LPS. Knockdown of Nrf2 is associated with increased levels of MafK, therefore the activity of Nrf2 could be involved in maintaining low levels of this protein, disallowing excessive p65 acetylation [45] .
Other interactors of Nrf2 and NF-κB components are presented in Figure 2 . However, in general, their role in modulating the balance between the two pathways remains to be further explored.
The importance of NF-κB and Nrf2 as targets in neurodegenerative diseases
Intensive research into anti-inflammatory properties of Nrf2 have identified it as a promising target in treating several neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and Parkinson's disease (PD). Several triterpenoids and phytochemical Nrf2-inducing compounds, such as CDDO-Im and SFP have shown promising results in reducing inflammation of the central nervous system (CNS) and importantly are also able to cross the blood-brain-barrier [24, 46, 47] . Drugs currently used in treating neurodegenerative disorders act primarily by regulating neuronal physiology through modulation of neurotransmitter release or by acting on neuronal receptors [48]. Importantly, Nrf2 has the potential to reduce numbers of overactive microglia and astrocytes, which are thought to make substantial contributors to CNS pathology [46, 48, 49] . In fact, the first drug approved by the U.S. Food and Drug Administration (FDA) in treatment of MS Tecfidera ® (dimethyl fumarate) is likely to act primarily through transcriptional activation of Nrf2 target genes and has a potent anti-inflammatory action [50] .
In addition to synthetic compounds that are used in disease settings, many phytochemicals naturally occurring in fruit and vegetables such as SFP, cinnamate, resveratrol or curcumin all have the potential to extenuate chronic inflammation. These compounds act by activating Nrf2 and increasing the antioxidant protection of the cells, to alleviate the damage from ROS [3, 24, 48] . Consuming Nrf2 activating compounds in food could therefore have a profound role in disease prevention.
Conclusions
Nrf2 and NF-κB are key pathways regulating the fine balance of cellular redox status and responses to stress and inflammation. The interplay between these pathways occurs through a range of complex molecular interactions and can often depend on the cell type and tissue context. These interactions operate through both transcriptional and posttranscriptional mechanisms, allowing fine-tuning of dynamic responses to ever-changing environmental cues. Despite convincing evidence for functional interactions between the Nrf2 and NF-κB pathways, many aspects of the conditional and dynamic nature of cross-talk remain unknown. As such, many important aspects of co-regulation, negative feedback and competitive binding are yet to be defined. Systematic investigation of protein complex composition and network analysis will provide new insights to drive development of rationally improved strategies to manipulate the balance between Nrf2 and NF-κB responses under both physiological and disease conditions. 
